Thanks to their feedback, were also investing in their career growth, with programs like CareerCare, which provides funding to help further their healthcare careers
Therefore, each quarter, Truveta Research provides a report describing first-time and overall prescribing of GLP-1 RA drugs
The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study
There is not enough research on its effects in pregnant women
Other companies are working on their own weight-loss pills: Eli Lilly, which makes Zepbound, is developing a GLP-1 pill, orforglipron, for weight loss and type 2 diabetes, with FDA approval anticipated for March 2026